A blood DNA methylation marker of cognitive ability is associated with six-year cognitive performance independent of blood Alzheimer’s disease biomarkers
The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences · 05.09.2026 · 81 (10)
DOI: 10.1093/gerona/glag222 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, online erschienen am 07.09.2026. Verfasst von Deirdre M O'Shea und 4 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, Florida, United States. Hauptthemen laut MEDLINE: Alzheimer Disease, DNA Methylation, Cognition. Die Arbeit nennt 33 Literaturangaben. Gefördert von: University of Miami Clinical and Translational Science Institute, National Institute on Aging and the National Institute of Neurological Disorders and Stroke.
Themen: Demenz
Abstract (Originalsprache)
MethylCog is a 29-CpG blood DNA methylation (DNAm) score developed to index general cognitive ability (g). Whether it captures cognition-related information associated with later cognitive performance that is not fully represented by blood-based biomarkers of Alzheimer’s disease and related dementias (ADRD) remains unclear. Using the held-out Health and Retirement Study Harmonized Cognitive Assessment Protocol (HRS-HCAP) test set from the original MethylCog study (N = 605), we examined associations with baseline g after adjustment for age, sex, education, apolipoprotein E (APOE) ε4 carrier status, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), phosphorylated tau 181 (p-tau181), and amyloid-β 42/40 ratio (Aβ42/40). Prospective associations with six-year follow-up g were examined after adjustment for baseline g, age, sex, education, and APOE ε4 carrier status, with additional adjustment for the ADRD biomarker panel. MethylCog remained associated with baseline g in the fully adjusted cross-sectional model (standardized β = .178, 95% CI: .111-.244, p < .001; ΔAdjR² = .025). MethylCog was also associated with six-year follow-up g after adjustment for baseline g and all covariates and biomarkers (standardized β = .101, 95% CI: .033-.170, p = .004; N = 331; ΔAdjR² = .007). Findings were similar among participants without baseline cognitive impairment. These findings provide preliminary evidence that a cognition-trained DNAm signature captures variation in later cognitive performance not fully represented by baseline cognition or available ADRD blood biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, Florida, United States.
- Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States.
ORCID-Profile: Deirdre M O'Shea
Förderung
- University of Miami Clinical and Translational Science Institute
- National Institute on Aging and the National Institute of Neurological Disorders and Stroke
Zitieren
APA
O'Shea, D. M., Wang, L., Lukacsovich, D., Zhang, W., & Galvin, J. E. (2026). A blood DNA methylation marker of cognitive ability is associated with six-year cognitive performance independent of blood Alzheimer’s disease biomarkers. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 81(10). https://doi.org/10.1093/gerona/glag222
Vancouver
O'Shea DM, Wang L, Lukacsovich D, Zhang W, Galvin JE. A blood DNA methylation marker of cognitive ability is associated with six-year cognitive performance independent of blood Alzheimer’s disease biomarkers. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. 2026;81(10). doi:10.1093/gerona/glag222
BibTeX
@article{OShea2026,
author = {O'Shea, Deirdre M and Wang, Lily and Lukacsovich, David and Zhang, Wei and Galvin, James E},
title = {A blood DNA methylation marker of cognitive ability is associated with six-year cognitive performance independent of blood Alzheimer’s disease biomarkers},
journal = {The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences},
year = {2026},
volume = {81},
number = {10},
doi = {10.1093/gerona/glag222}
}
EUVIMED